Backs FY25 revenue view 6.7%-7.7%. The company said, “The Company is maintaining reported revenue growth and adjusted2 earnings per share guidance and narrowing full-year 2025 constant currency and organic constant currency revenue growth guidance to reflect currency expectations.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target lowered to $105 from $112 at Barclays
- Notable companies reporting before tomorrow’s open
- ZBH Upcoming Earnings Report: What to Expect?
- Zimmer Biomet: FDA grants BDD for iodine-treated total hip replacement system
- Zimmer Biomet: FDA grants BDD for treated total hip replacement system